Adverse reactions to etiological treatment in patients with Chagas disease in the Western Potiguar mesoregion of Brazil: a cross-sectional study
Keywords:
Chagas disease, Drug-related side effects and adverse reactions, Drug therapy, Benznidazole, Etiological treatment, PreventionAbstract
BACKGROUND: Chagas disease is a significant public health challenge in Brazil that is characterized by substantial morbidity and mortality rates, coupled with limited etiological treatment options.
OBJECTIVE: To describe and assess the occurrence of adverse reactions resulting from benznidazole treatment in patients from the Western Potiguar mesoregion of Brazil.
DESIGN AND SETTING: This retrospective, longitudinal, descriptive observational study included 106 individuals with Chagas disease who attended the Chagas Disease Outpatient Clinic of the Universidade do Estado do Rio Grande do Norte.
RESULTS: Among patients subjected to etiological treatment with benznidazole, 40.5% (43/106) experienced adverse reactions, manifesting in 13 distinct forms. The most prevalent reactions occurred primarily in the dermatological and hematological systems. Thus, despite the notable frequency of adverse reactions, their severity remained low, as evidenced by the minimal treatment suspension rate. The treatment demonstrated potential benefits to those affected by the disease.
CONCLUSIONS: This study characterized the most frequent adverse reactions to benznidazole, mainly dermatological and hematological reactions, which were mostly mild and rarely led to treatment suspension. Recognizing these events is essential for guiding professionals, enhancing patient confidence, and improving adherence to etiological treatments for Chagas disease.
Downloads
References
Chagas disease in Latin America: an epidemiological update based on 2010 estimates. Wkly Epidemiol Rec. 2015;90(6):33–43. PMID: 25671846.
Pereiro AC, Lenardón M, Zeballos A, et al. Reporting of adverse reactions to benznidazole: does medical expertise matter? Rev Panam Salud Publica. 2018;42:e69. https://doi.org/10.26633/RPSP.2018.69.
Validade do conceito de forma indeterminada de doença de Chagas. Rev Soc Bras Med Trop. 1985;18(1):46. https://doi.org/10.1590/S0037-86821985000100010.
Martins K, Andrade CM, Barbosa-Silva AN, et al. Trypanosoma cruzi III causing the indeterminate form of Chagas disease in a semi-arid region of Brazil. Int J Infect Dis. 2015;39:68–75. PMID: 26327123; https://doi.org/10.1016/j.ijid.2015.08.012.
Martins-Melo FR, Ramos AN Júnios, Alencar CH, Heukelbach J. Prevalence of Chagas disease in Brazil: a systematic review and meta-analysis. Acta Trop. 2014;130:167–74. PMID: 24139912; https://doi.org/10.1016/j.actatropica.2013.10.002.
Dias JCP, Machado EMM, Fernandes AL, Vinhaes MC. Esboço geral e perspectivas da doença de Chagas no Nordeste do Brasil. Cad Saúde Pública. 2000;16:S13–S34. https://doi.org/10.1590/S0102-311X2000000800003.
Tacconi VFS, Saldanha JSTT, Melo TA, et al. Epidemiologia da doença de Chagas no estado do Rio Grande do Norte no período entre 2018 e 2022. Braz J Infect Dis. 2023;27:103528. https://doi.org/10.1016/j.bjid.2023.103528.
Andrade CM, Câmara ACJ, Nunes DF, et al. Chagas disease: morbidity profile in an endemic area of Northeastern Brazil. Rev Soc Bras Med Trop. 2015;48:706–15. https://doi.org/10.1590/0037-8682-0235-2015.
Brito CR, Sampaio GH, Câmara AC, et al. Seroepidemiology of Trypanosoma cruzi infection in the semiarid rural zone of the State of Rio Grande do Norte, Brazil. Rev Soc Bras Med Trop. 2012;45(3):346–52. PMID: 22760134; https://doi.org/10.1590/s0037-86822012000300013.
Marin JÁ Neto, Rassi A Júnior, Oliveira GMM, et al. SBC guideline on the diagnosis and treatment of patients with cardiomyopathy of Chagas disease, 2023. Arq Bras Cardiol. 2023;120(6):e20230269. PMID: 37377258; https://doi.org/10.36660/abc.20230269.
Gascon J, Bern C, Pinazo MJ. Chagas disease in Spain, the United States and other non-endemic countries. Acta Trop. 2010;115(1/2):22–7. PMID: 19646412; https://doi.org/10.1016/j.actatropica.2009.07.019.
Caldas IS, Santos EG, Novaes RD. An evaluation of benznidazole as a Chagas disease therapeutic. Expert Opin Pharmacother. 2019;20(15):1797–807. PMID: 31456439; https://doi.org/10.1080/14656566.2019.1650915.
Patterson S, Wyllie S. Nitro drugs for the treatment of trypanosomatid diseases: past, present, and future prospects. Trends Parasitol. 2014;30(6):289–98. PMID: 24776300; https://doi.org/10.1016/j.pt.2014.04.003.
Trochine A, Creek DJ, Faral-Tello P, Barrett MP, Robello C. Benznidazole biotransformation and multiple targets in Trypanosoma cruzi revealed by metabolomics. PLoS Negl Trop Dis. 2014;8(5):e2844. PMID: 24853684; https://doi.org/10.1371/journal.pntd.0002844.
Guedes PM, Silva GK, Gutierrez FR, Silva JS. Current status of Chagas disease chemotherapy. Expert Rev Anti Infect Ther. 2011;9(5):609–20. https://doi.org/10.1586/eri.11.31.
Ferreira AM, Damasceno RF, Monteiro RS Júnior, et al. Reações adversas ao benzonidazol no tratamento da doença de Chagas: revisão sistemática de ensaios clínicos randomizados e controlados. Cad Saúde Colet. 2019;27(3):354–62. https://doi.org/10.1590/1414-462x201900030456.
Viotti R, Vigliano C, Lococo B, et al. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities. Expert Rev Anti Infect Ther. 2009;7(2):157–63. PMID: 19254164; https://doi.org/10.1586/14787210.7.2.157.
Tornheim JA, Lozano Beltran DF, Gilman RH, et al. Improved completion rates and characterization of drug reactions with an intensive Chagas disease treatment program in rural Bolivia. PLoS Negl Trop Dis. 2013;7(9):e2407. PMID: 24069472; https://doi.org/10.1371/journal.pntd.0002407.
Cancado JR. Long term evaluation of etiological treatment of chagas disease with benznidazole. Rev Inst Med Trop Sao Paulo. 2002;44(1):29–37. PMID: 11896410.
Dias JCP, Coura JR. Clínica e terapêutica da doença de Chagas: uma abordagem prática para o clínico geral [Internet]. Editora Fiocruz; 1997 [cited 2025 Nov 11]. Available from: https://books.scielo.org/id/nf9bn.
Sperandio da Silva GM, Mediano MF, Alvarenga Americano do Brasil PE, et al. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole. Antimicrob Agents Chemother. 2014;58(11):6371–7. PMID: 25114135; https://doi.org/10.1128/AAC.02842-14.
Carrilero B, Murcia L, Martínez-Lage L, Segovia M. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country. Rev Esp Quimioter. 2011;24(3):123–6. PMID: 21947093.
Pinazo MJ, Muñoz J, Posada E, et al. Tolerance of benznidazole in treatment of Chagas’ disease in adults. Antimicrob Agents Chemother. 2010;54(11):4896–9. PMID: 20823286; https://doi.org/10.1128/AAC.00537-10.
Evans RS, Lloyd JF, Stoddard GJ, Nebeker JR, Samore MH. Risk factors for adverse drug events: a 10-year analysis. Ann Pharmacother. 2005;39(7/8):1161–8. PMID: 15897265; https://10.1345/aph.1E642.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68(9):1781–90. PMID: 14620598.
Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684–700. PMID: 21480948; https://doi.org/10.1111/j.1365-2125.2010.03774.x.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 São Paulo Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
